Slide 1: Exchange filing cover letter: Earnings Presentation
^ franced enzymes Where EI\IZYME is Life Advanced Enzyme Technologies Ltd. CIN: L24200MH1989PLC051018 Sun Magnetica, A wing, 5 th Floor, LIC Service Road, Louiswadi, Thane ( W ) -400 604, India Tel: + 91-22-4170 3200, Fax: + 91 -22- 2583 5159 Email: info@ advancedenzymes.com, www.advancedenzymes.com
Slide 2: Advanced Enzyme Technologies Limited Earnings Presentation May 2026
^ Klvancec! enzymes Where ENZYME is Life Advanced Enzyme Technologies Limited Earnings Presentation | May 2026
Slide 3: Safe Harbour Statement
Safe Harbour Statement ^ Manced enzymes Where ENZYME is Life This presentation contains forward-looking statements that reflect management’s current views with respect to certain future events and potential financial performance. Forward-looking statements are other than statements of historical fac
Slide 4: Table of Contents
^ Mancecl enzymes Where ENZYME is Life 2 Performance Summary | Q4 FY26 Business Performance PAGE: 4 PAGE: 07 4 Geographical Performance Result Summary | Q4 FY26 PAGE: 11 PAGE: 12 6 Unique Investment Case Focus Area Going Ahead PAGE: 26 PAGE: 28 TABLE OF CONTENTS Shareholders’ Information PAGE: 29 Ea
Slide 5: Results Summary - Q4 FY26 (Consolidated) Y-o-Y
Results Summary - Q 4 FY26 (Consolidated) Y-o-Y Advanced enzy 77705 >: \ IV: Revenue (₹ mn) EBITDA (₹ mn) PAT (₹ mn) I l 22% 2,034 39% 632 69% l 453 1,672 456 267 Q4 FY25 Q4 FY26 Q4 FY25 Q4 FY26 Q4 FY25 Q4 FY26 Revenue grew by 22% on y-o-y basis to EBITDA grew by 39% to ₹ 632 million in Q4 PAT incre
Slide 6: Results Summary - Q4 FY26 (Consolidated) Q-o-Q
Results Summary - Q 4 FY26 (Consolidated) Q-o-Q Advanced enzy 77705 >: \ IV: Revenue (₹ mn) EBITDA (₹ mn) PAT (₹ mn) l l 18% 28% 5% I 2,034 632 453 432 1,719 494 Q3 FY26 Q4 FY26 Q3 FY26 Q4 FY26 Q3 FY26 Q4 FY26 Revenue grew by 18% on q-o-q basis to ₹ 2,034 million in EBITDA grew by 28% to ₹ 632 milli
Slide 7: Results Summary - FY26 (Consolidated) YTD
Results Summary - FY26 (Consolidated) YTD Advanced enzy 77705 >: \ IV: Revenue (₹ mn) EBITDA (₹ mn) PAT (₹ mn) 18% 30% l l l 17% 7,458 1,944 2,291 1,736 6,369 1,340 FY25 FY26 FY25 FY26 FY25 FY26 Revenue grew by 17% on YTD basis to EBITDA grew by 18% to ₹ 2,291 million in PAT increased to ₹ 1,736 mil
Slide 8: Human Nutrition
Human Nutrition ^ Manced enzymes Wherp FN7YMFn Life (₹ in (₹ in Million) Million) Q4 FY26 Q4 FY25 FY26 FY25 +24% 1,281 1,031 of Sales +15% 4,674 4,053 of Sales Commentary: Commentary: 1,221 1,212 1,281 1,024 1,012 1,018 1,031 • The human nutrition segment contributed around • The human nutrition seg
Slide 9: Animal Nutrition
Animal Nutrition ^ Manced enzymes Wherp FN7YMFn Life (₹ in (₹ in Million) Million) Q4 FY26 Q4 FY25 FY26 FY25 +19% 250 209 of Sales +25% 946 760 of Sales Commentary: Commentary: 260 244 250 • The animal nutrition segment contributed around • The animal nutrition segment contributed around I 12% durin
Slide 10: Industrial Bio-processing
Industrial Bio-processing ^ Manced enzymes Wherp FN7YMFn Life Q4 FY26: ₹276 mn Food (₹ in (₹ in Million) Million) 14% Q4 FY26 Q4 FY25 FY26 FY25 Q4 FY26: ₹47 mn +17% 324 278 of Sales +16% 1,176 1,018 of Sales Non-Food 2% Commentary: Commentary: 361 • The Industrial Bio-Processing segment contributed
Slide 11: Specialized Manufacturing
Specialized Manufacturing ^ Manced enzymes Wherp FN7YMFn Life (₹ in (₹ in Million) Million) Q4 FY26 Q4 FY25 FY26 FY25 +17% 180 154 of Sales +23% 662 539 of Sales Commentary: Commentary: 185 180 • This segment contributed about 9% during the • This segment contributed about 9% during the year 154 154
Slide 12: Geographical performance
Geographical performance enzymes Wherp FN7YMFn Life India Americas Europe W Asia* Rest of the World 52% 28% 5% 12% 3% Q4 FY26 1,061 Q4 FY26 573 Q4 FY26 95 Q4 FY26 249 Q4 FY26 57 Q4 FY26 Q4 FY25 704 Q4 FY25 646 Q4 FY25 102 Q4 FY25 181 Q4 FY25 40 +51% -11% -7% +38% +44% 50% 30% 5% 12% 3% FY26 3,727 FY
Slide 13: Profit & Loss (Consolidated) - Q4 FY26 & FY26
Profit & Loss (Consolidated) - Q 4 FY26 & FY26 Advanced enzy 77705 > : \ IV: (₹ in Million) Q4 FY26 Q3 FY26 Q4 FY25 Y-o-Y Q-o-Q FY26 FY25 Y-o-Y Particulars Audited Un-Audited Audited (%) (%) Audited Audited (%) Income from Operations 2,034 1,719 1,671 +22% +18% 7,458 6,369 +17% Expenses 1,503 1,328
Slide 14: Balance Sheet (Consolidated)
Balance Sheet (Consolidated) pnzvmpp Wherp FN7YMFn Life (₹ in Million) FY26 FY25 FY24 FY23 FY22 Particulars Audited Audited Audited Audited Audited Assets Property, plant and equipment 2,758 2,929 2,765 2,732 2,622 Capital work-in-progress 512 217 411 215 151 Intangible assets 469 523 479 550 609 Go
Slide 15: Strong Financial Performance - FY26
Strong Financial Performance - FY26 Advanced enzy 77705 > : \ IV : Revenue from Operations EBIDTA & EBIDTA Margin (%) 7,458 2,500 31% 50% 6,369 L 6,239 38% L 45% 5,406 31% 5,294 2,000 33% 40% 29% 35% 1,500 30% 25% 1,000 20% 15% 500 10% 2,014 1,564 2,045 1,944 2,291 5% 0 0% FY 22 FY 23 FY 24 FY 25 FY
Slide 16: Strong Financial Performance - FY26
Strong Financial Performance - FY26 Advanced enzymes Where ENZYME Is Life Net Working Capital (Days) Net Worth (? mn) 16,320 146 L 14,209 13,241 12,351 10,886 138 i 135 135 132 FY 22 FY 23 FY 24 FY 25 FY 26 FY 22 FY 23 FY 24 FY 25 FY 26 ROE (%) & ROCE (%) Net Debt to Equity (x) 15.93% 0.02 0.02 13.0
Slide 17: Annexure
co) — S x< co) = S <x
Slide 18: Company Overview
Company Overview ^^ ancpcl enzymes Where ENZYME is Life Advanced Enzymes is a research driven company with global <fg> leadership in the manufacturing of enzymes and probiotics. We are committed to providing eco-safe solutions to a wide variety of industries like human health care and nutrition, ani
Slide 19: Advanced Enzyme Technologies Limited - A Rising Global Star
Advanced Enzyme Technologies Limited - A Rising Global Star Advanced enzy 77705 > : \ IV: 9 7 1st 2nd 2nd R&D Units Manufacturing Units Indian enzyme Highest market Listed integrated India – 5 | USA – 1 | India - 8 | USA - 1 company share in India enzyme player globally Germany –1 68+ 400+ 700+ 45+
Slide 20: Brief History and Evolution
Brief History and Evolution enzymes Wherr FN7YMFn Life Incorporated as R&D locations Advanced • Equity investment • Floated IPO • 4 food enzymes got • Received NIH grant • Received approval Advanced (Thane and Sinnar) Biochemicals Ltd. is by Kotak Private • Acquired 70% stake approved as a for Immun
Slide 21: Board of Directors
Board of Directors enzymes Wherr FN7YMFn Life r T 1 Mr. Vasant Rathi Mr. Mukund Kabra Mr. Pramod Kasat Ms. Rasika Rathi Mr. Vinod Jajoo Promoter Chairman Whole-time Director Independent Director Non-Executive Director Independent Director and Non-Executive Director \ m ' 4 <7 . 'T ' . * JSEj S Q 1 \
Slide 22: Management Team
Management Team enzymes Wherr FN7YMFn Life Mr. Beni Prasad Rauka Mr. Harshad Doshi Ms. Rasika Rathi Group - Chief Financial Officer CFO & COO - Advanced Enzymes, USA General Counsel / Vice President And Secretary – Advanced Enzymes, USA 0HHiW ^ t^ • - «r : k h i i _ Ms. Martina Doering Mr. Michael P
Slide 23: How Big is the Opportunity?
How Big is the Opportunity? enzymes Wherr FN7YMFn Life o Global Probiotics Market Global Enzymes Market Animal Probiotics $1Bn 7% $16 Bn Grow at a CAGR Grow at a CAGR 14.12% 7.80% $4.55Bn CY 2024-29 till 2029 $8Bn $13Bn Human Probiotics $12Bn 93% $3.57Bn $3.57Bn Competitive Scenario in the Global En
Slide 24: What we are Aiming in the Opportunity?
What we are Aiming in the Opportunity? enzymes Wherr FN7YMFn Life AETL’s Current Share of Revenue Addressable market for AETL CARG(%) over next Focus Area Opportunity Size over next 5 years** 5 years FY26 FY25 Human Nutrition Pharma/API $ 80 mn $ 50 mn 6% $ 24.90 mn, 29% $ 18.04 mn, 24% Probiotics $
Slide 25: What Makes AETL a Unique Investment Case?
What Makes AETL a Unique Investment Case? Advanced enzy 77705 > : \ IV: Integrated Player Specialized Significant Focus with Presence Business with on International Across the High Entry Markets & Brand Enzyme Barriers Building Value Chain Inherent Strong Research Diversification Strong Financial &
Slide 26: Integrated Player with Presence Across the Enzyme Value Chain
Integrated Player with Presence Across the Enzyme Value Chain Advanced enzy 77705 > : \ IV: Research & Development Manufacturing Marketing & Distribution . co Earnings Presentation | May 2026 25
Slide 27: Specialized Business With High Entry Barriers
Specialized Business With High Entry Barriers enzymes Wherr FN7YMFn Life Technocrat Promoters Global Competitiveness Cumulative experience of 7+ decades Amongst the Lowest Cost Manufacturers in the in the global enzyme industry World (Benchmarked both in terms of Capex & Opex) Sustained Research & D
Slide 28: Future Growth Drivers
Future ^^ rinrpri enzymos Where ENZYME is Life Growth Drivers Continued Broaden & Deepen Inorganic Investment in R&D Geographical Presence Expansion o Acquisition of Key Technologies, Competencies & o Identify Product gaps and Develop new Enzymes, o Increased focus on high return applications where
Slide 29: Focus Areas Going Ahead
Focus enzymes • ZiU' tP ' /• Areas Going Ahead Animal Nutrition Probiotics Bio-Catalysis Baking • Continuing conduct trials and studies to bring • To introduce more probiotics products in • Developing bio catalysis for API manufacturers, • In Bio-processing division, our focus is on newer and effect
Slide 30: Shareholders Information
Shareholders Information Advanced enzymes Where ENZYME Is Life Stock Data Stock Chart 4 Market Capitalization (₹) 28,575 mn Shares Outstanding 111.93 mn 267.55 255.30 Symbol (NSE/ BSE) ADVENZYMES / 540025 Mar-25 Apr-25 May-25 Jun-25 Jul-25 Aug-25 Sep-25 Oct-25 Nov-25 Dec-25 Jan-26 Feb-26 Mar-26 Sour
Slide 31: Thank You
THANK YOU Malvan Tadka - HIcMUl d Scbl Pipeline Advanced Enzyme Technologies advanced enzymes Advanced Enzyme Technologies Limited Address: 5th Floor, 'A' wing, Where ENZYME is Life Sun Magnetica LIC Service Road, Louiswadi, Thane (W) 400 604, India Tel: +91-22-4170 3200 Fax: + 91-22-25835159 Web: w